NMN and NR FDA Approval History: What the Regulatory Record Actually Shows

The direct answer

Neither NMN nor NR has FDA drug approval, and neither has ever had a New Drug Application or Biologics License Application submitted on its behalf for any indication. NR is currently sold as a dietary supplement without an active FDA challenge to that status. NMN is also sold as a dietary supplement, but the FDA's December 2022 response to a citizen petition tentatively raised the possibility that NMN does not meet the legal definition of a dietary supplement, because a pharmaceutical company's earlier investigational new drug (IND) filing for NMN was made public before NMN supplements reached the market. The agency has not finalized that determination, and enforcement has not followed. That combination, an open legal question with no enforcement action, is the single most important fact for anyone evaluating NMN products or protocols today.

Not approved does not mean banned

The absence of drug approval does not make NMN or NR illegal to sell or use. Dietary supplements in the United States are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA, a supplement ingredient generally does not require pre-market approval. Manufacturers are responsible for ensuring safety, and the FDA must act after the fact if it wants to restrict or remove a product, rather than approving it beforehand. This is a fundamentally different regulatory posture than for prescription drugs, and it explains why supplement shelves can carry compounds that have never gone through an efficacy review.

NR has moved through this supplement framework with relatively little friction. NMN has not.

The drug exclusion question that separates NMN from NR

Section 331(ll) of the Federal Food, Drug, and Cosmetic Act, often called the drug exclusion clause, blocks a substance from being marketed as a dietary supplement if it was already authorized for investigation as a new drug, and that investigation was made public, before it appeared as a supplement ingredient. This fits into FDA's broader framework for supplement regulation.

Public reporting indicates that a pharmaceutical company filed an investigational new drug application involving a proprietary NMN formulation around 2021, and that this filing became public. Citizen petitions subsequently asked the FDA to clarify whether that IND triggers exclusion for NMN supplement products generally. The FDA's December 2022 response reportedly acknowledged that NMN "may be excluded" from the dietary supplement definition on this basis but stopped short of a final determination. This account is drawn from secondary reporting on the petition response rather than a primary document link verified for this article, and any exact wording attributed to the FDA in secondary sources should be checked against the agency's own docket before it is repeated as a direct quotation in patient-facing material.

What is not in dispute: the FDA has not published a final rule resolving NMN's status, has not conducted a mass enforcement sweep against NMN supplement manufacturers, and NMN products remain broadly available through major retailers as of this writing. Readers should treat the regulatory status as unresolved rather than as either a green light or a ban.

NR: a comparatively settled supplement record

NR's regulatory path has drawn less controversy. Its primary commercial developer submitted a New Dietary Ingredient notification and a Generally Recognized as Safe (GRAS) notification to the FDA years before the NMN drug-exclusion question arose, and NR has continued to be sold as a supplement without a public FDA challenge to that status. Background on how NDI notifications work is available from the FDA's New Dietary Ingredient Notification Process page.

It is worth being precise about what an accepted NDI notification or a GRAS no-objection letter actually means. Neither is an approval. Both indicate that the FDA did not object to the safety case the manufacturer submitted for a specific use level in a specific product; neither involves an independent FDA efficacy review, and neither authorizes any disease-related claim.

No publicly disclosed drug-exclusion challenge comparable to NMN's has been raised against NR as of this writing, but that could change if a pharmaceutical IND for NR became public in the future, following the same legal mechanism that produced NMN's current situation.

What the human trial evidence actually shows

Human data on both compounds follow a consistent pattern: NAD+ biomarkers respond, but downstream clinical outcomes have not been established in adequately powered trials.

A widely cited trial in postmenopausal women with prediabetes and overweight or obesity tested a modest daily dose of oral NMN against placebo over roughly ten weeks. It found that skeletal muscle NAD+ increased in the NMN group, but insulin-stimulated glucose disposal, the outcome most relevant to prediabetes, did not improve significantly compared with placebo. A separate randomized, placebo-controlled trial testing NMN at doses reportedly up to roughly 1,200 mg per day for about twelve weeks in healthy adults found no dose-limiting toxicity and no clinically significant change in liver, kidney, or blood count measures over that period.

For NR, a small crossover trial in healthy older men reported that a gram-scale daily dose over a few weeks raised whole blood NAD+ substantially, without serious adverse events, though the study was not powered for clinical endpoints. A separate placebo-controlled trial in obese men testing a higher daily NR dose over twelve weeks found a clear shift in NAD+ metabolism but no significant difference from placebo in insulin sensitivity, body weight, blood pressure, or lipid measures.

These trial descriptions are based on how the studies have been characterized in secondary reporting reviewed for this article. The exact PubMed identifiers and journal citations attached to these trials in earlier drafts of this content could not be independently verified against the primary literature during this review, and any specific dose, sample size, or duration figure quoted here should be re-confirmed against the original published papers before being used to support clinical decisions or repeated as a precise citation.

No trial identified in this review, for either compound, has demonstrated a pre-specified clinical endpoint benefit, such as reduced cardiovascular events, reduced all-cause mortality, or a defined HbA1c reduction, in an adequately powered study. That gap is the clearest explanation for why neither compound has pursued or received FDA drug approval: raising a biomarker is not the same evidentiary bar as demonstrating a health outcome.

What labels can legally say

Because neither NMN nor NR is an approved drug, neither may carry a disease claim, language stating or implying that the product diagnoses, treats, cures, mitigates, or prevents a disease, under FDA's structure/function claims framework. Permitted structure/function claims, such as "supports healthy NAD+ levels," must carry the standard disclaimer that the statement has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease.

Marketing language referencing "anti-aging" effects, disease risk reduction, or cellular repair claims for NMN or NR products would generally fall outside what a supplement label may legally state. Whether any particular product's current marketing crosses that line is a product-by-product question; a general claim that a specific fraction of currently sold products violate labeling rules cannot be supported here without a verifiable, dated audit, and none is available for this review.

Compounding pharmacies and telehealth NAD-optimization protocols

Some compounding pharmacies and telehealth clinics include NMN in personalized formulas. This practice generally relies on the 503A compounding exemption, which allows a pharmacist to compound a preparation for an individual patient under a valid prescription without FDA approval of the compounded product itself, subject to other statutory limits.

There is a real legal tension here. If NMN is eventually determined to fall under the drug exclusion clause, treating it as a compounded drug ingredient under a prescription is arguably more consistent with the FDA's own tentative position than selling the same molecule over the counter as a supplement. That does not mean compounded NMN is risk-free; it means the compliance question is different, and it depends on the individual pharmacy's own regulatory posture, which patients and clinicians cannot verify from a product label alone.

Post-market safety monitoring: what exists and what does not

The FDA maintains a voluntary adverse event reporting system, MedWatch, and a supplement-specific parallel, the CFSAN Adverse Event Reporting System (CAERS). Both are searchable by ingredient name. A specific report count for NMN or NR in either database changes over time and was not independently re-verified for this article; readers who need a current figure should query the databases directly rather than rely on a static number in an article like this one.

A structural gap worth noting: because NMN and NR are not approved prescription drugs and are not reimbursed through insurance, they do not appear in claims-based drug safety surveillance systems that track long-term outcomes across large populations. Voluntary adverse event reports capture only what patients or clinicians choose to submit, which understates the true rate of any adverse effect and cannot establish long-term safety on its own.

What is established, what is plausible, and what is not established

Established: Neither NMN nor NR has FDA drug approval. NR's supplement status has not faced a public drug-exclusion challenge. NMN's supplement status is the subject of an open, unresolved FDA inquiry following a 2022 citizen-petition response. Both compounds raise NAD+-related biomarkers in short human trials lasting weeks, not years.

Plausible but unproven: That raising NAD+ biomarkers translates into a measurable clinical benefit (improved insulin sensitivity, reduced cardiovascular risk, slowed functional aging) in general or specific populations. That short-term safety data at the doses tested extend safely to years of continuous use or to patients with comorbidities.

Not established: Any FDA-approved therapeutic indication for either compound. Any completed, adequately powered trial demonstrating a hard clinical endpoint. A final FDA ruling on whether NMN supplements are lawfully marketable given the drug-exclusion question. Long-term human safety data beyond roughly twelve weeks in the trials reviewed here.

A decision framework for clinicians and informed patients

This framework does not tell a reader what to take. It maps which facts should change a decision, and what to do when the facts are missing.

Step 1: Which compound are you evaluating?

• If NR: proceed to Step 2 using the "settled supplement" facts below.
• If NMN: proceed to Step 2 using the "contested supplement" facts below, and treat the regulatory ambiguity as a standing fact of the recommendation, not a footnote.
• If a compounded NAD+ or NMN injectable/IV product: stop and treat this as a separate, higher-uncertainty category (see Step 4).

Step 2: What does the regulatory record actually support, right now?

Step 3: What tradeoff does the ambiguity actually create? For NR, the practical risk is mainly the ordinary supplement risk: unproven efficacy, no independent quality assurance beyond what the manufacturer submitted. For NMN, there is an added layer: a live possibility that the FDA could later restrict its supplement sale, which does not retroactively harm a patient who already used it, but does mean a clinician who documents a recommendation today is documenting a recommendation made under acknowledged legal uncertainty. That is a disclosure obligation, not a reason by itself to avoid the compound.

Step 4: Exceptions that change the calculus

• Patients with a personal or strong family history of cancer: the theoretical concern about NAD+ repletion and tumor biology raised in some preclinical models has not been resolved by human oncologic safety data for either compound; this warrants an explicit conversation and, if relevant, oncology input before use.
• Patients on complex polypharmacy or with hepatic or renal impairment: none of the short-term trials reviewed here enrolled these populations, so the reassuring safety data do not transfer to them without independent verification.
• Compounded or IV NAD+ products: these fall outside the NDI/GRAS supplement pathway described above and outside standard 503A review unless a specific pharmacy has affirmatively reviewed its own compliance posture; treat as a distinct, higher-uncertainty category requiring pharmacy-specific legal confirmation, not an extension of oral supplement safety data.

Step 5: What to document, regardless of the choice made Record that the patient was informed: (1) neither compound is FDA-approved for any indication, (2) NMN's supplement status is under open regulatory question, (3) short-term trial data exist but long-term and endpoint data do not, and (4) the recommendation will be revisited if the FDA issues a final determination on NMN.

Where clinical guidance stands

No major evidence-based clinical guideline reviewed for this article endorses NMN or NR for any indication, and no completed guideline recommendation supersedes the trial gap described above. Readers should not interpret the absence of a guideline endorsement as equivalent to a safety warning; it reflects the absence of outcome-level trial evidence, which is a different and more basic evidentiary gap than a documented harm.

When to seek urgent or specialist care instead of self-directing supplementation

NAD-precursor supplements are not treatments for diagnosed metabolic disease, and delaying evaluation of new symptoms such as unexplained weight loss, persistent fatigue, or abnormal lab values in favor of a supplement protocol is not supported by the evidence reviewed here. Anyone considering NMN, NR, or a compounded NAD+ product alongside an existing diagnosis or prescription regimen should raise it with the prescribing clinician first, particularly given the unresolved questions about long-term safety and drug interactions.